Sanofi Other Current Assets 2010-2024 | SNY

Sanofi other current assets from 2010 to 2024. Other current assets can be defined as field containing the sum of all current assets that cannot be standardized into another field as well as those that are aggregated by the company because materially, they are too small to list separately.
  • Sanofi other current assets for the quarter ending September 30, 2024 were $M, a NAN% increase year-over-year.
  • Sanofi other current assets for 2023 were $3.756B, a 0.92% increase from 2022.
  • Sanofi other current assets for 2022 were $3.721B, a 11.92% decline from 2021.
  • Sanofi other current assets for 2021 were $4.225B, a 6.25% decline from 2020.
Sanofi Annual Other Current Assets
(Millions of US $)
2023 $3,756
2022 $3,721
2021 $4,225
2020 $4,506
2019 $3,643
2018 $3,445
2017 $2,266
2016 $2,447
2015 $1,962
2014 $2,867
2013 $3,038
2012 $3,029
2011 $3,437
2010 $11,999
2009 $11,779
Sanofi Quarterly Other Current Assets
(Millions of US $)
2024-09-30
2024-06-30 $4,168
2024-03-31
2023-12-31 $3,756
2023-09-30
2023-06-30 $3,676
2023-03-31
2022-12-31 $3,721
2022-09-30
2022-06-30
2022-03-31
2021-09-30
2021-03-31
2020-09-30
2020-03-31
2019-09-30
2019-03-31
2018-03-31
2017-12-31 $2,266
2017-09-30
2017-06-30 $2,301
2017-03-31
2016-12-31 $2,447
2016-09-30
2016-06-30 $2,002
2016-03-31
2015-09-30
2015-06-30 $2,400
2014-06-30 $2,845
2013-06-30 $2,714
2012-06-30 $2,606
2012-03-31
2011-12-31 $3,437
2011-09-30
2011-06-30 $2,892
2011-03-31
2010-12-31 $11,999
2010-09-30
2010-06-30 $12,103
2010-03-31
2009-12-31 $11,779
2009-09-30
2009-06-30 $2,700
2009-03-31
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $128.465B $46.611B
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
Stock Name Country Market Cap PE Ratio
Eli Lilly (LLY) United States $790.248B 81.85
Novo Nordisk (NVO) Denmark $489.545B 35.30
Johnson & Johnson (JNJ) United States $373.278B 15.14
AbbVie (ABBV) United States $308.242B 16.23
Merck (MRK) United States $254.810B 16.93
Novartis AG (NVS) Switzerland $215.989B 14.36
AstraZeneca (AZN) United Kingdom $200.887B 17.90
Pfizer (PFE) United States $148.702B 10.17
Innoviva (INVA) United States $1.259B 10.48